News
OCGN
1.170
-0.85%
-0.010
Alphabet To Rally Around 14%? Here Are 10 Top Analyst Forecasts For Monday
Susquehanna raised the price target for Occidental Petroleum Corporation from $70 to $81 on Friday. Chardan Capital increased Ocugen, Inc. Price target from $4 to $5. Keybanc boosted the price targets for Alphabet Inc. And ConocoPhillips.
Benzinga · 3d ago
Key Takeaways From Ocugen Analyst Ratings
4 analysts have expressed a variety of opinions on Ocugen (NASDAQ:OCGN) over the past quarter. The company has an average price target of $6.5 and a 12-month revenue growth rate of 142.6%. The company is developing a gene therapy platform to treat retinal diseases. Oc Eugen Inc is a company focused on discovering and developing novel gene and cell therapies.
Benzinga · 3d ago
Ocugen Is Maintained at Buy by Chardan Capital
Dow Jones · 3d ago
Ocugen Price Target Raised to $5.00/Share From $4.00 by Chardan Capital
Dow Jones · 3d ago
Chardan Capital Maintains Buy on Ocugen, Raises Price Target to $5
Benzinga · 3d ago
Weekly Report: what happened at OCGN last week (0415-0419)?
Weekly Report · 3d ago
Ocugen: Two Gene Therapy Data Readouts In 2024 To Drive Value
Seeking Alpha · 5d ago
Ocugen Says It Has Completed Dosing of Subjects With Geographic Atrophy In Cohort 2 Of Phase 1/2 ArMaDa Clinical Trial Of OCU410—A Modifier Gene Therapy
OCU410 is a gene therapy candidate being developed for geographic atrophy. GA is an advanced stage of dry age-related macular degeneration. GA affects approximately 1 million people in the United States. Company says dosing is complete in the second cohort of its Phase 1/2 clinical trial for OCU410.
Benzinga · 6d ago
OCUGEN ANNOUNCES DOSING COMPLETION OF SUBJECTS WITH GEOGRAPHIC ATROPHY IN COHORT 2 OF PHASE 1/2 ARMADA CLINICAL TRIAL OF OCU410—A MODIFIER GENE THERAPY
Reuters · 6d ago
Ocugen stock jumps after $175M securities filing
Seeking Alpha · 04/18 10:21
OCUGEN INC FILES FOR MIXED SHELF OF UP TO $175 MLN - SEC FILING
Reuters · 04/18 10:02
OCGN Stock Earnings: Ocugen Beats EPS for Q4 2023
Ocugen reported earnings per share of -4 cents for the fourth quarter of 2023. The company reported revenue of $6.04 million. Ocugen's results were above the analyst estimate for EPS of -6 cents. The stock was down 1.7% after the market closed.
Investorplace · 04/17 02:53
OCUGEN, INC. Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the fiscal year ended December 31, 2023
Press release · 04/16 22:35
3 Standout Penny Stocks to Watch This April
Penny stocks are stocks that trade for less than $5 per share. Ocugen, Inc. (OCGN), Veru Inc (VERU), and Desktop Metal, Inc (DM) are three outperforming penny stocks trading under $2. Veru Veru stock has surged 82.6% on a YTD basis, but is 31% below its 52-week high.
Barchart · 04/16 12:34
Weekly Report: what happened at OCGN last week (0408-0412)?
Weekly Report · 04/15 10:22
The 'Undercovered' Dozen From March 2024
Home Stock Ideas Quick Picks & Lists The 'Undercovered' Dozen From March 2024. The "Undercovered" Dozen series highlights 12 ideas from the previous month on stocks that receive limited coverage on Seeking Alpha. B2Gold Corp. Has been covering the sale of its shares.
Seeking Alpha · 04/12 18:30
Ocugen to Participate in Fireside Chat at the Emerging Growth Virtual Healthcare Equity Conference, Presented by Noble Capital Markets
Ocugen, Inc. Is a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines. Dr. Shankar Musunuri will participate in a fireside chat during the Emerging Growth Virtual Healthcare Equity Conference. The conference will take place from April 17 – 18, 2024.
Barchart · 04/12 06:30
EQUITY ALERT: Rosen Law Firm Files Securities Class Action Lawsuit on Behalf of Ocugen, Inc. Incorporated Investors – OCGN
Rosen Law Firm has filed a class action lawsuit on behalf of purchasers of securities of Ocugen, Inc. Between May 8, 2020 and April 1, 2024. The lawsuit seeks to recover damages for ocugen investors under the federal securities laws. A class action has already been filed.
Barchart · 04/11 11:09
Ocugen says EU backs a U.S. trial for gene therapy
Healthcare Ocugen says EU backs a U.S. Trial for gene therapy candidate, OCU400. Company hopes to obtain regulatory approval for the company’s gene therapy in 2026 for rare eye disorder retinitis pigmentosa. Ocugen shares traded higher on Wednesday after the company said EU backed a u.S.-based trial.
Seeking Alpha · 04/10 14:20
The Law Offices of Frank R. Cruz Announces Investigation of Ocugen, Inc. (OCGN) on Behalf of Investors
The Law Offices of Frank R. Cruz announces an investigation of Ocugen, Inc. On behalf of investors concerning the Company’s possible violations of federal securities laws. On April 1, 2024, Oc Eugen disclosed that it had identified certain accounting errors. The Company's stock price fell 10.4% on April 2, 2024.
Barchart · 04/10 14:13
More
Webull provides a variety of real-time OCGN stock news. You can receive the latest news about Ocugen Inc through multiple platforms. This information may help you make smarter investment decisions.
About OCGN
Ocugen, Inc. is a biopharmaceutical company. The Company is focused on discovering, developing, and commercializing gene and cell therapies, biologics, and vaccines that improve health for patients across the globe. Its technology pipeline includes modifier gene therapy platform, regenerative medicine cell therapy platform, and biologic therapies for retinal diseases. The Company is developing its modifier gene therapy platform, inclusive of OCU400, OCU410, and OCU410ST, for the treatment of multiple inherited retinal disease (IRDs), including retinitis pigmentosa (RP), Leber congenital amaurosis (LCA), Stargardt disease and multifactorial diseases such as dry age-related macular degeneration (dAMD) and geographic atrophy (GA). It is developing an inhalation-based mucosal vaccine platform based on a novel ChAd vector, which includes OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine.